| Document |
Document Title |
|
JP3403218B2 |
PURPOSE: To provide a new compound useful as an antiliphemic and for treating liver disorders with cholestasis with no side-effects, which has activity to decrease the cholesterol level in the serum and has high affinity for transport sy...
|
|
JP2003119154A |
To prevent or treat diseases due to androgen deficiency.In at least either of the treatment or the prevention of diseases due to androgen deficiency, a glucocorticoid receptor antagonist is used. A glucocorticoid receptor antagonist suit...
|
|
JP2003513102A |
The invention relates to novel 18-norsteroids (gonatrienes) of general formula (I), wherein R<1>, R<2>, R<3>, R<6>, R<7>, R<8>, R<9>, R<11>, R<11'>, R<14>, R<15>, R<15'>, R<16>, R<17> and R<17'> have the meaning cited in the description,...
|
|
JP2003508542A |
The invention relates to novel C13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates of general formula (I), in which R1 represents the acyl radical, oxycarbonyl radical, aminocarbonyl radical, sulfonyl radical or aminosulfonyl radical ...
|
|
JP3377856B2 |
A compound represented by the following formula: X-Y-Z, wherein Y is represented by any of the formulae (III) to (V), X represents a monovalent group of a tetracycline compound, and Z represents a monovalent group of a stereoid compound ...
|
|
JP3378245B2 |
Angiostatic steroids for use in controlling neovascularization and ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatic steroids and methods for their use in treating neovascularization and ocular hypertensio...
|
|
JP2003504644A |
The invention relates to a method for screening therapeutic agents, defined as SCAP antagonists, for use in combating diseases associated with elevated lipid levels, said method comprising detecting or assaying the extent or result of tr...
|
|
JP2003026697A |
To provide a cosmetic treatment method for improving the appearance of keratin substances such as the skins, hair, eyelashes and nails, especially for preventing or treating the symptom of skin ageing and/or skin darkening and/or the pig...
|
|
JP2003503419A |
This invention describes a 11beta-long-chain-substituted estratriene of general formula (I), in which R<11 >is a long-chain radical that has a nitrogen atom and optionally a sulfur atom, which in addition can be functionalized in the ter...
|
|
JP2003501363A |
Disclosed are cationic lipids for gene transfer, which are capable of transferring nucleic acid materials into cells at very high efficiency with low cell toxicity. They are synthesized by forming a carbamate ester linkage between lysine...
|
|
JP2002544137A5 |
|
|
JP2002544137A |
Formula (I) in which: R1 and R2, which may be the same or different, each represents a lower alkyl, alkenyl or alkynyl group; R3 represents a methyl group having alpha- or beta-configuration; R4 represents a hydrogen atom or an etherifyi...
|
|
JP2002543216A |
Steroid derivatives of this invention interact with nuclear liver X receptor (LXR) and ubiquitous receptor (UR) and can be used to treat a variety of LXR- or UR-mediated disorders.
|
|
JP3356525B2 |
The invention relates to the compounds (I): R = oxo or beta -OH and A and B represent a free or protected 3-keto- DELTA <4> or DELTA <1,4> residue, their preparation, their application to the preparation of the compounds (A): R3 is a hyd...
|
|
JP3356478B2 |
Complexes which contain at least one glycosyl-phosphatidylinositol protein and at least one cholanic acid derivative of the formula I (I) are suitable, inter alia, in enzyme tests and as aids in chemical reactions; where R1 is -NH-CH2-CH...
|
|
JP3357427B2 |
17-(3-Furyl) and (4-pyridazinyl)-5 beta ,14 beta -androstane derivatives of formula (I) wherein the symbol @ , the symbol ---, Y, R, R<1>, R<2> and R<3> have the meaning indicated in the specification. Processes of making the said compou...
|
|
JP2002542162A |
A steroidal compound or a salt thereof having the following general formula: A-B-C-N(O) 2 (I) for the treatment of oxidative stress.
|
|
JP2002540215A |
Novel glucocorticoid receptor ligands and methods of treating diseases such as diabetes, wherein the ligands have general formula (I)wherein the variables are as defined by the present specification.
|
|
JP3350048B2 |
A method of treatment of androgen-related diseases such as prostate cancer in susceptible male animals, including humans, comprises administering novel antiandrogens and/or novel sex steroid biosynthesis inhibitors as part of a combinati...
|
|
JP3349279B2 |
Novel compounds for use in electrochemiluminescent assays and characterised by containing the structure X - Y - ZwhereinX represents one or more nucleotides which may be the same or different, one or more amino aci...
|
|
JP2002539134A |
The invention relates to 22R-hydroxycholesta-8,14-diene derivatives having general formula (I) wherein R1 is OR, OS03H or =NOR; with R being H, (C1-6)alkyl or (C1-6)acyl; each of R2 and R3 is independently hydrogen or (C1-6)alkyl; R4 is ...
|
|
JP2002539152A |
Compounds and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject are described. Neurological or cognitive conditions are treated by administering to a subject an effect...
|
|
JP2002538123A |
The invention relates to (androst-5-en-17beta-yl)alkylsulfoxides and sulfones having general formula (I), wherein R1, R2, R3, X and Y are defined in the specification. The compounds of the invention have meiosis inhibiting activity and c...
|
|
JP3340514B2 |
The subject of the invention is a process for the preparation of the compound of formula (I): characterised in that the corresponding 9 alpha -OH compound is treated with chlorosulphonic acid in an organic solvent.
|
|
JP2002536456A |
The present invention relates to pharmaceutically active unsaturated cholestane derivatives, to pharmaceutical compositions comprising them as active substances and to the use of these novel compounds for the preparation of medicaments. ...
|
|
JP2002536455A |
3,16-Dihydroxy-1,3,5(10)-estratriene derivatives (I) are new. 3,16-Dihydroxy-1,3,5(10)-estratriene derivatives of formula (I) are new: [Image] thick black line in ring = single or double bond; R 1>H, halo, OH, Me, CF 3, OMe or OEt; R 2>H...
|
|
JP2002308776A |
To provide a medicinal composition useful in the therapy for human prostatic adenocarcinoma.The medical composition for treating human prostatic adenocarcinoma contains a 5-α-reductase inhibiting compound such as 17β-(N-t- butylcarboxy...
|
|
JP3337689B2 |
Compounds of the formula or a pharmaceutically acceptable salt or ester thereof, wherein R1 is selected from the group consisting of hydrogen and C1-10 alkyl; R2 is selected from the group consisting of hydrogen and C1-10 alkyl; R3 is se...
|
|
JP2002533471A |
The invention relates to new 7 alpha , 17 alpha , 17 beta -substituted testosterone derivatives of general formula (I) and their use as pure antiandrogens for the long-term therapy of androgen-dependent diseases, notably for the long-ter...
|
|
JP3332377B2 |
A therapeutic combination, useful in the treatment or prevention of benign prostatic hyperplasia, includes an antiestrogen and at least one further active ingredient selected from the group consisting of inhibitors of aromatase activity ...
|
|
JP2002531542A |
Serine carbonates of formula I are precursors for organoleptic compounds, masking agents and antimicrobial agents. Further they are alternative substrates for malodor producing enzymes. The symbols in formula I are defined in claim 1.
|
|
JP2002255993A |
To obtain a pharmacological composition effective for treating an estrogen-dependent tumor.This pharmacological composition comprises a pharmacologically acceptable carrier or diluent and a compound which contains a ring system and a sul...
|
|
JP2002523422A |
The present invention relates to novel compounds comprising a steroid hormone linked to a DNA-interacting molecule that target nucleic acids to the cell nucleus. Further, the invention relates to a method for introducing nucleic acids in...
|
|
JP3308094B2 |
PURPOSE: To stereoselectively obtain the composition useful as intermediate product for production of medicaments from an easily available starting compound in high yield and with a secure method by using specific hydroxy cholanic acid e...
|
|
JP2002522501A |
Newly isolated aminosterol compounds and pharmaceutical compositions based on the aminosterol compounds are described. Methods for the treatment of various disorders, for example, a microbial infection, are also described.
|
|
JP2002518516A5 |
|
|
JP3292318B2 |
PURPOSE: To obtain the captioned polymers which exert favorable influences on enterohepatic circulation, reduce cholesterol concentration in blood, exhibit superior remedial effects and are useful for the prevention of arteriosclerosis b...
|
|
JP2002516816A |
The invention concerns dietary fat compositions that contain the hydroxy acid or dicarboxylic acid or amino acid esters of a phytosterol and/or phytostanol, or the mixed esters formed with the alcohols, polyols or polyol (C2 . . . C22)-f...
|
|
JP2002153270A |
To provide a method for facilitating the transfer of nucleic acids into cells, and to provide a novel cationic amphiphile useful for this purpose.This method for facilitating the transfer for nucleic acids into cells, comprises preparing...
|
|
JP3286321B2 |
An aminosterol antibiotic, (3 beta (N-[3-aminopropyl]-1,4-butanediamine)-7 alpha ,24 zeta -dihydroxy-5 alpha -cholestane 24-sulfate), which can be isolated from the stomach of the common dogfish shark, Squalus acanthias, is disclosed.
|
|
JP2002515035A |
A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharm...
|
|
JP2002511482A5 |
|
|
JP3273010B2 |
To obtain a compound useful for treating a disease corresponding to a sex steroid. This sex steroid inhibitor has a molecular structure of formula I (a dotted line is a double bond; R5 and R6 are each H, hydroxyl, etc.; R100 is a divalen...
|
|
JP2002510295A |
New non-estrogenic derivative compounds of estradiol, which have no estrogenic activity and comparatively high anti-oxidative activity, are disclosed. These new non-estrogenic derivative compounds are potentially useful as non-estrogenic...
|
|
JP2002506077A |
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17beta-hydroxys...
|
|
JP2002506433A |
Crystal comprising at least part of the ER alpha ligand binding domain, optionally bound to a ligand, ligands that bind to ER receptors, and methods of designing them, and a homology model of the ER beta receptor.
|
|
JP2002060384A |
To obtain a compound useful for treating breast cancer or other diseases promoted by their exacerbation due to the activation of sex steroid receptor, and to provide a medicament composition containing the above compound.This compound ha...
|
|
JP2002505292A |
A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromicin and novobiocin.
|
|
JP2002505336A |
Novel sterol derivatives of formula (I), in which: R1 represents a hydroxyl group or protected hydroxyl group, R2 represents a hydrogen atom and a double bond is present at c, or R1 and R2 together represent an oxo group and a double bon...
|
|
JP3258661B2 |
A method for facilitating the transfer of nucleic acids into cells comprising preparing a mixed lipid dispersion of a cationic lipid with a co-lipid in a suitable carrier solvent. The lipid has a structure which includes a lipophilic gro...
|
